Go to content

News

Filters

Changing any of the form inputs will cause the content to refresh with the filtered results.

Skip filters

Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024

Read about Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024

PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery

Read about PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery

Papp et al. (2025) “CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery” Molecular Therapy.

DOI: 10.1016/j.ymthe.2025.03.018

Read about Papp et al. (2025) “CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery” Molecular Therapy.

PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection

Read about PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection

Broomfield et al. (2025) “Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection” Journal of Experimental Medicine.

DOI: 10.1084/jem.20241148

Read about Broomfield et al. (2025) “Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection” Journal of Experimental Medicine.

PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT

Read about PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT

Blizard et al. (2025) “Monitoring mRNA vaccine antigen expression in vivo using PET/CT” Nature Communications.

DOI: 10.1038/s41467-025-57446-w

Read about Blizard et al. (2025) “Monitoring mRNA vaccine antigen expression in vivo using PET/CT” Nature Communications.

PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA

Read about PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA

Yanik et al. (2025) “iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA” NPJ Vaccines.

DOI: 10.1038/s41541-025-01089-x

Read about Yanik et al. (2025) “iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA” NPJ Vaccines.

Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel

Read about Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel

Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics

Read about Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics

Acuitas Therapeutics’ President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program

Read about Acuitas Therapeutics’ President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program